These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 3698032

  • 1. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC, Markman M, Cleary S, Howell SB.
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES, Baselga J, Smart TB, Magill GB, Markman M, Ranhosky A.
    Cancer Chemother Pharmacol; 1991 Jun; 28(1):51-4. PubMed ID: 2040033
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M, Moore EC, Burgess AM, Marti JR, Russ J, Plunkett W, Loo TL, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1980 Jun; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract] [Full Text] [Related]

  • 14. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
    Chan TC, Howell SB.
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
    [Abstract] [Full Text] [Related]

  • 15. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982 Apr; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 16. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 Aug 15; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 18. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
    Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL.
    Cancer Res; 1980 Sep 15; 40(9):3163-6. PubMed ID: 7427934
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 20. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V, Van Oosterom A, Mouridsen HT, Cheix F, Somers R, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 01; 18(1):81-4. PubMed ID: 6211362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.